Joaquim Bosch-Barrera
Joaquim Bosch-Barrera
Catalan Institute of Oncology (ICO). University of Girona. Girona Biomedical Research Institute
Correu electrònic verificat a iconcologia.net
Títol
Citada per
Citada per
Any
Metformin: multi-faceted protection against cancer
S Del Barco, A Vazquez-Martin, S Cufí, C Oliveras-Ferraros, ...
Oncotarget 2 (12), 896, 2011
2982011
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ...
The Lancet Oncology 19 (4), 521-536, 2018
1752018
Metformin-induced preferential killing of breast cancer initiating CD44+ CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast …
S Cufí, B Corominas-Faja, A Vazquez-Martin, C Oliveras-Ferraros, ...
Oncotarget 3 (4), 395, 2012
1462012
Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy
J Bosch-Barrera, JA Menendez
Cancer treatment reviews 41 (6), 540-546, 2015
932015
STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis
N Priego, L Zhu, C Monteiro, M Mulders, D Wasilewski, W Bindeman, ...
Nature medicine 24 (7), 1024-1035, 2018
752018
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
A Vazquez-Martin, S Cufí, C Oliveras-Ferraros, VZ Torres-Garcia, ...
Scientific reports 3, 2560, 2013
682013
Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells
B Corominas-Faja, E Cuyàs, J Gumuzio, J Bosch-Barrera, O Leis, ...
Oncotarget 5 (18), 8306, 2014
662014
Stem cell-like ALDHbright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the …
B Corominas-Faja, C Oliveras-Ferraros, E Cuyas, A Segura-Carretero, ...
Cell cycle 12 (21), 3390-3404, 2013
612013
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
S Cufí, R Bonavia, A Vazquez-Martin, C Oliveras-Ferraros, ...
Scientific reports 3, 2459, 2013
612013
Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205
S Cufí, A Vazquez-Martin, C Oliveras-Ferraros, R Quirantes, ...
Cell Cycle 11 (6), 1235-1246, 2012
602012
Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR …
S Cufí, R Bonavia, A Vazquez-Martin, B Corominas-Faja, ...
Food and chemical toxicology 60, 360-368, 2013
462013
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
C Oliveras-Ferraros, S Cufi, B Queralt, A Vazquez-Martin, ...
British journal of cancer 106 (8), 1406-1414, 2012
422012
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
E Cuyàs, S Fernández-Arroyo, B Corominas-Faja, E Rodríguez-Gallego, ...
Oncotarget 6 (14), 12279, 2015
402015
Targeting STAT3 with silibinin to improve cancer therapeutics
J Bosch-Barrera, B Queralt, JA Menendez
Cancer treatment reviews 58, 61-69, 2017
392017
Calorimetric study of blends of low density polyethylene (LDPE) and linear low density polyethylene (LLDPE) temperature rising elution fractionation (TREF) fractions
PL Joskowicz, A Muñoz, J Barrera, AJ Müller
Macromolecular Chemistry and Physics 196 (1), 385-398, 1995
381995
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
N Karachaliou, J Codony-Servat, C Teixidó, S Pilotto, A Drozdowskyj, ...
Scientific reports 5, 17499, 2015
372015
Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation
C Oliveras-Ferraros, S Cufí, A Vazquez-Martin, OJ Menendez, ...
Cell Cycle 11 (5), 865-870, 2012
372012
Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
JA Menendez, R Quirantes-Piné, E Rodríguez-Gallego, S Cufí, ...
Oncotarget 5 (9), 2344, 2014
362014
Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin
J Bosch-Barrera, E Sais, N Cañete, J Marruecos, E Cuyàs, A Izquierdo, ...
Oncotarget 7 (22), 32006, 2016
332016
Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy
E Castañon, J Bosch-Barrera, I López, V Collado, M Moreno, ...
Journal of translational medicine 11 (1), 13, 2013
332013
En aquests moments el sistema no pot dur a terme l'operació. Torneu-ho a provar més tard.
Articles 1–20